secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001628280-25-038927
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera reports Q2 net loss $34.7M, revenue up 134% YoY; starts Phase 1 for VMS drug ABCL635
--------------------------------------------------------------------------------

- Revenue $17.1M vs $7.3M YoY (134% increase); net loss $34.7M ($0.12 loss per share) vs $36.9M ($0.13) prior year.
- First participants dosed in Phase 1 trial of ABCL635 for vasomotor symptoms; initial data expected mid-2026.
- Cumulative partner-initiated program starts reached 102 (+9 YoY); molecules in clinic 18 (+4 YoY).
- Net loss per share $(0.12) versus $(0.13); R&D expenses $39.2M, G&A $19.0M.
- Total liquidity of $753M including $580M cash/securities and $173M in non-dilutive government funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000162828025038927/0001628280-25-038927-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000162828025038927/abcl-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-038927

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer